Lantheus Holdings, Inc.
LNTHNext catalyst
LNTH2403 Phase 1 dose
Relapsed / Refractory Osteosarcoma
Get an email about LNTH's next catalysts
Track Lantheus Holdings (LNTH) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
LNTH2403 Phase 1 dose Phase 2 Est. Readout
Primary completion for LNTH2403 Phase 1 dose trial (NCT07357519) in Relapsed / Refractory Osteosarcoma
SourceMarket Overview
Stock performance and key metrics
DEFINITY
Cardiac Disease
DEFINITY®
Cardiac Disease
Sestamibi
Kawasaki Disease
[18F]florbetaben
Cardiac Amyloidosis
[18F]PI-2620
Alzheimer Disease
Florbetaben (BAY94-9172)
Alzheimer Disease
Ultrasound contrast agent (Contrast-enhanced ultrasound)
Hepatocellular Carcinoma
[68Ga]-LNTH-2401
Prostate Cancer
99mTechnicium (sestamibi or tetrofosmin)
Coronary Artery Disease
Flurpiridaz F18
Coronary Artery Disease
LNTH2403 Phase 1 dose
Relapsed / Refractory Osteosarcoma
Perflutren lipid microsphere
Von-Hippel Lindau
Sulfur hexafluoride lipid microspheres
Von-Hippel Lindau
BMS747158
Ischemia
Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D)
Relapsed / Refractory Osteosarcoma
Technetium Tc99m Sestamibi
Kawasaki Disease
Peflutren Lipid Microsphere Injectable Suspension
Liver Disease
18F-DCFPyL
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DEFINITY | Phase 3 | Cardiac Disease | - | - |
DEFINITY® | Phase 3 | Cardiac Disease | - | - |
Sestamibi | Phase 3 | Kawasaki Disease | - | - |
[18F]florbetaben | Phase 3 | Cardiac Amyloidosis | - | - |
[18F]PI-2620 | Phase 3 | Alzheimer Disease | - | - |
Florbetaben (BAY94-9172) | Phase 3 | Alzheimer Disease | - | - |
Ultrasound contrast agent (Contrast-enhanced ultrasound) | Phase 3 | Hepatocellular Carcinoma | - | - |
[68Ga]-LNTH-2401 | Phase 3 | Prostate Cancer | - | - |
99mTechnicium (sestamibi or tetrofosmin) | Phase 3 | Coronary Artery Disease | - | - |
Flurpiridaz F18 | Phase 3 | Coronary Artery Disease | - | - |
LNTH2403 Phase 1 dose | Phase 2 | Relapsed / Refractory Osteosarcoma | - | - |
Perflutren lipid microsphere | Phase 2 | Von-Hippel Lindau | - | - |
Sulfur hexafluoride lipid microspheres | Phase 2 | Von-Hippel Lindau | - | - |
BMS747158 | Phase 2 | Ischemia | - | - |
Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D) | Phase 2 | Relapsed / Refractory Osteosarcoma | - | - |
Technetium Tc99m Sestamibi | Phase 2 | Kawasaki Disease | - | - |
Peflutren Lipid Microsphere Injectable Suspension | Phase 2 | Liver Disease | - | - |
18F-DCFPyL | Phase 2 | Prostate Cancer | - | - |
Frequently asked questions
What is in Lantheus Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 18 drug candidates in Lantheus Holdings, Inc.'s (LNTH) pipeline across Phase 3, Phase 2. Its lead program is [18F]florbetaben (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Lantheus Holdings, Inc.'s next FDA catalyst?→
Lantheus Holdings, Inc.'s (LNTH) next tracked catalyst is a Phase 2 readout expected August 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LNTH biotech catalysts?→
Add LNTH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Lantheus Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.